Diltiazem provides anti-ischemic and anti-arrhythmic protection in patients undergoing coronary bypass grafting.
In 91 patients undergoing elective coronary bypass grafting, the anti-ischemic and anti-arrhythmic efficacy of a 24-hour infusion of either the calcium antagonist diltiazem (0.1 mg/kg per h, n = 44) or nitroglycerin (1 micrograms/kg per min, n = 47) were compared. Myocardial ischemia was diagnosed by Holter monitoring and the repeated assessment of 12-lead ECG and serum enzyme levels and defined as a transient ischemic event, transient coronary spasm or myocardial infarction. The two groups did not differ with respect to preoperative and operative data. Postoperatively, the average heart rate and pulse pressure rate were significantly lower in the diltiazem group. The incidence of postoperative atrial fibrillation (4.5 vs 19.1%, P < 0.01), transient coronary spasm (2.3 vs 11.4%, P < 0.05) and myocardial infarction (4.5 vs 8.5%, not significant) and the frequency of ventricular premature couplets/h (12.1 +/- 4.5 vs 18.1 +/- 5.1, P < 0.05) and ventricular runs/h (2.5 +/- 0.8 vs 6.5 +/- 2.8, P < 0.05) were lower in the diltiazem as compared to the nitroglycerin group. In addition, diltiazem-treated patients had significantly lower postoperative peak values of creatine kinase-MB (19.3 +/- 11.6 vs 29.3 +/- 20.6, P < 0.05). In conclusion, perioperative infusion of diltiazem is effective in reducing the incidence and extent of arrhythmias and myocardial ischemia in patients undergoing elective coronary bypass grafting as compared to patients receiving nitroglycerin.
Hannes
W
W
Department of Cardiovascular Surgery, University of Freiburg, Germany.
Fasol
R
R
Zajonc
H
H
Schindler
M
M
Schumacher
B
B
Schlosser
V
V
Holubarsch
C H
CH
Seitelberger
R
R
D001145:Arrhythmias, Cardiac / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D001026:Coronary Artery Bypass; D003402:Creatine Kinase / Q000097:blood; D004110:Diltiazem / Q000627:therapeutic use*; D015716:Electrocardiography, Ambulatory; D005260:Female; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D005996:Nitroglycerin / Q000627:therapeutic use*; D011446:Prospective Studies
D007527:Isoenzymes; D003402:Creatine Kinase; D004110:Diltiazem; D005996:Nitroglycerin